1月9日，港股集体高开，恒生指数涨0.47%，报26272.54点，恒生科技指数涨0.38%，报5699.97点，国 企指数涨0.35%，报9070.91点，红筹指数涨0.45%，报4112.86点。 盘面上，大型科技股多走高，阿里巴巴涨3.79%，京东集团涨3.31%，小米集团涨0.16%，网易涨 0.09%，美团跌0.99%，快手跌0.9%，哔哩哔哩涨2.95%；石油股普涨，中石油涨超1%；中资券商股活 跃，东方证券涨近1%；生物医药板块回调，百济神州跌超3%；今日三只新股上市，集体高开，瑞博生 物-B涨超29%，MINIMAX涨超42%，金浔资源涨超26%。 企业新闻 迅销(06288.HK)：发布截至2025年11月30日止三个月第一季度业绩，收入10277.45亿日元，同比增加 14.8%；净利润1474.45亿日元，同比增加11.7%。 捷利交易宝(08017.HK)：2025年12月，新增机构客户数量7个，同比增长1个；注册用户数量为约88.67 万，同比增长6.2%；打新用户数量约11.38万，同比增长8.4%。 迪米生活控股(01667.HK)：附属与合作方订立战略合作框架协议，以进军电子雾 ...

中新网山西新闻1月5日电(任丽娜) 冬意渐浓的韩国首都首尔，因一场跨越山海的产业之约，迎来了晋韩 合作蓬勃涌动的春潮。 2025年12月28日至31日，值此岁序更替、辞旧迎新之际，山西省投资促进局代表团赴韩国开展了一系列 投资促进活动，通过宣传推介、恳谈对接、拜访交流等形式，全面展示山西省转型发展新成果和对外开 放新形象，有力推动了晋韩产业合作向更高层次、更宽领域、更深维度发展。 恳谈凝共识共话新愿景 2025年12月29日，山西省投资促进局在首尔举办了以"携手合作共向未来"为主题的中国(山西)—韩国产 业合作恳谈会。双方代表齐聚一堂，共话产业融合发展新愿景。 山西省投资促进局副局长刘乙佑在中国(山 西)—韩国产业合作恳谈会上致辞并作专题推介。山西省投资促进局供图 山西省投资促进局副局长刘乙佑在致辞并作专题推介时表示，山西作为中华文明的重要发祥地之一，不 仅蕴藏着文旅康养的丰富资源，更以制造业振兴升级和绿色转型为双翼，全力拥抱新质生产力。他从生 物医药、现代农业、制造业振兴升级等方面介绍了山西的优势与成果，并热情邀请韩国朋友到山西感受 发展热度与投资机遇，在山西投资兴业、大展宏图。并诚邀韩国各界来山西领略华夏 ...

继上周五大涨迎来开门红后，港股三大指数今日呈现窄幅震荡行情，截至收盘，恒生指数微幅上涨 0.03%，国企指数跌0.22%，恒生科技指数微涨0.09%。 （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 出品丨21财经客户端 南财快讯工作室 | 名称 | 现价 | 涨跌幅 -- | | --- | --- | --- | | 蔚来-SW | 38.860 | -5.95% | | 9866.HK | | | | 小鹏汽车-W | 76.650 | -4.60% | | 9868.HK | | | | 零跑汽车 | 47.880 | -3.39% | | 9863.HK | | | | 比亚迪股份 | 95.800 | -2.99% | | 1211.HK | | | | 长城汽车 | 14.190 | -6.15% | | 2333.HK | | | | 吉利汽车 | 17.600 | -3.30% | | 0175.HK | | | 生物医药股涨幅居前，荣昌生物涨超7%。2025年12月31日，CDE官网显示，荣昌生物维迪西妥单抗新 适应症拟纳入突破性治疗品种。此外，1月3日晚间，国家药 ...

转变作风优化营商环境，通过打造"十分钟政务服务圈"，超600项高频事项实现"家门口"办理，工程建 设项目审批时间压减65%，推动151个项目"拿地即动工"。 攻坚"工改"拓展产业空间，中山直面土地低效利用、产业空间不足之困，坚定不移打赢打好"工改"攻坚 战，2022年以来出台87项新政策，累计拆除整理低效工业用地超5.2万亩，项目容积率从改造前不足0.6 提高到3.0以上，已建成厂房使用率超83%，新招引项目和增资扩产投资预计超2000亿元。 与港澳合作也同步深化，在全省率先实现"港药粤产"，"港澳药械通"批件增至25个、指定医疗机构增至 3家，165项政务服务实现"跨境通办"，成为"粤车南下"首批4个城市之一。 "十四五"时期，面对发展中的短板，中山以"转作风、再出发、开新局"的决心，坚定不移打赢打好转作 风、村镇低效工业园改造升级（下称"工改"）、治水三大攻坚战。 2025年12月31日，"十四五"广东成就系列新闻发布会中山专场召开。据发布会消息，"十四五"期间，中 山地区生产总值连续跨越3500亿、4000亿元关口，预计2025年将突破4200亿元。经营主体总量达74万 户，五年增长60%；省级产业园区 ...

Group 1 - The core concept of the news is the rapid emergence and development of One Person Companies (OPC) in the Yangtze River Delta, driven by a shift in investment attraction logic from large projects to fostering individual innovation and micro-entrepreneurship [1][2][3] - The Yangtze River Delta is witnessing a structural shift in investment strategies, moving from "big project attraction" to "probability investment," focusing on nurturing distributed micro-innovation units to mitigate risks associated with large-scale projects [2][3] - The development of OPCs is supported by a comprehensive action plan that includes the establishment of a development alliance and service packages covering computing power, data, finance, and training [1] Group 2 - The emergence of OPCs is not uniform across the Yangtze River Delta; different regions are adapting the concept to their unique industrial bases and market needs, resulting in varied implementation strategies [4][5] - In Shanghai, the focus is on compliance and professional services, while in Jiangsu, OPCs serve as "industry patches" addressing specific engineering challenges in manufacturing [4][5] - Zhejiang's OPC model emphasizes "plugin-style innovation" and commercialization acceleration, while Anhui focuses on front-end validation, highlighting the diverse approaches to OPC development across the region [5][6] Group 3 - The successful integration of OPCs into the industrial chain depends on establishing a collaborative network that connects individual innovations with real market demands, transforming dispersed trial points into deliverable and reusable industrial increments [3][4] - To enhance the effectiveness of OPCs, three foundational capabilities need to be established: standardized rules for cross-city operations, accessible resources for individual innovators, and a reliable demand pipeline to ensure sustainable delivery [7][8][9] - The government and local authorities are encouraged to transition from mere subsidy providers to active participants in rule design and demand facilitation, ensuring that the OPC ecosystem can thrive beyond initial enthusiasm [9]

同时，支持关键技术攻关。在广西科技计划项目申报指南中设置医药、医疗器械相关方向，支持珍 稀濒危中药资源繁育、仿生、替代技术研发及中药材育种攻关。支持北部湾特色优势海洋中药资源普 查、开发与技术攻关，建设海洋生物医药种质资源库。 支持中药大品种二次开发，新靶点、新机制、 新结构研究，以及高端医疗器械与医用材料研制。支持突破基于人工智能与生物模型驱动的高通量筛选 和药物设计、高附加值化学原料药绿色合成等关键技术。鼓励企业开展仿制药质量和疗效一致性评价， 对符合豁免生物等效性试验原则的，按品种类型给予不超过150万元支持；对需开展体内生物等效性试 验的，按品种类型给予不超过400万元支持。 日前，自治区政府办公厅印发《关于推动广西生物医药产业高质量发展的若干政策措施》，旨在进 一步提升产业特色化、集聚化与智能化水平，打造广西特色资源型医药、生物制造与大健康产业链供应 链，建设面向东盟的重要生物医药制造基地，推动产业高质量发展。 在促进产业化发展方面，对新取得国家药品或医疗器械注册批件并落地生产的企业，按注册分类和 产业化规模给予支持。其中，1类创新药不超过3000万元，2类改良型新药不超过1000万元，3类化学 药 ...

【全省扫描】今年以来，国际环境复杂多变，不稳定性、不确定性增加。作为经济大省，江苏勇挑 大梁、攻坚克难，于风浪中把稳舵盘，在承压中夯实根基，持续筑牢"四稳"的坚实底座，让高质量发展 的航船内核更稳、动力更足。 稳就业，托起民生"幸福盘"。就业是民生之本，也是发展的温度计，全省坚持稳存量、扩增量、提 质量并重，制定实施新一轮稳岗促就业政策，重点帮扶受外部冲击较大的外贸企业与中小微企业稳定岗 位，聚焦高校毕业生、农民工等重点群体精准施策，前10个月，全省城镇新增就业118.3万人，"稳稳的 就业"托举起群众"满满的幸福"。 时已冬至，江苏大地上依旧色彩斑斓、活力涌动。 在"十四五"规划收官之年的最后"关口"回望，一年来，全省上下面对复杂严峻的外部环境和经济运 行中的困难挑战，全力巩固拓展经济回升向好势头，迎难而上、聚力攻坚、奋力拼搏，全年地区生产总 值预计突破14万亿元，有力扛起了经济大省挑大梁的责任担当。 经济总量"再上台阶"的背后，既有动人的高光时刻，也有稳健的整体提升，让我们通过4个"关键 词"，回顾梳理江苏经济这不平凡的一年。 "四稳"：巩固拓展经济回升向好势头 【高光时刻】4月18日，省发展改革委与江苏 ...

Market Overview - The Hang Seng Index has a short-term support reference at 25,000 points, with a recent increase in trading volume and a year-to-date gain of 26.96% [1][3] - The U.S. Federal Reserve announced a 0.25% interest rate cut, marking the third consecutive reduction this year, with expectations for further cuts in 2026 and 2027 [2][4] Company News - Xiaomi (1810) plans to invest approximately 40 billion yuan in R&D in 2026, with a total investment of 200 billion yuan over the next five years [8] - Tencent (0700) has launched its mixed reality model 1.5, allowing users to create interactive worlds using text or images [8] - JD.com (9618) has reopened its digital collectibles business, allowing new digital assets to be transferred [8] - Vanke Enterprises (2202) is reportedly seeking to delay interest payments to some lenders [8] - SenseTime (0020) raised 3.15 billion yuan through a discounted share placement [8] Industry Insights - The macroeconomic environment shows a slight increase in China's public budget revenue, with a year-on-year growth of 0.8% [6] - The real estate sector has seen a 28.5% year-on-year increase in bond financing in November [6] - The Chinese passenger car market's retail sales of new energy vehicles fell by 4% year-on-year in the first two weeks of December [6] - The establishment of a national unified electricity market evaluation system is underway, focusing on operational effectiveness and market competition [6]

高质量发展大潮奔涌向前。项目是强引擎，是硬支撑，更是赢得未来的关键。 近年来，济南的发展轨迹，正由一棒又一棒的项目攻坚接续铺就。从"项目突破年"到"项目深化年"，济 南以"项目"这一关键抓手，持续推动城市能级跃升。 2025年是"十四五"规划收官之年，也是加快绿色低碳高质量发展的关键一年。面对外部环境不确定性的 挑战，济南继续聚焦"项目"这一发展关键，以"项目提升年"，将项目建设推向更深层次、更广领域。 机器人产业作为人工智能与高端制造深度融合的前沿领域，正成为济南培育新质生产力的重要突破口。 在平阴县玫瑰镇的乐聚(济南)人形机器人数据训练中心的训练场内，人形机器人正通过多模态感知与自 主学习，完成复杂地形行走、精细操作等高难度动作。该中心于11月初试运行，是全省最大、全市首个 人形机器人训练场。这一项目的运行是济南加快机器人产业集聚发展的缩影之一。 今年以来，济南聚焦机器人产业链关键环节，引进多个高精尖项目，涵盖核心零部件研发、整机制造到 场景应用全链条。一批本土企业加速成长，在工业机器人、服务机器人等领域实现技术突破。 行至岁尾，回眸全年。 一个个重大项目如春笋破土，拔节生长，勾勒出城市跃升的强劲脉动。 ...

Core Viewpoint - In the context of profound changes in the pharmaceutical industry, HaiTe Biopharma is adopting a dual-track strategy of "innovation and imitation" to navigate through policy and market fluctuations, aiming to capture opportunities amid challenges [2]. Group 1: Company Strategy - HaiTe Biopharma has successfully launched two national class I new drugs and recognizes the significant impact of policies and funding on the pharmaceutical industry [3]. - The company is expanding its product line to include generic drugs in response to market changes and aims to participate in national procurement to quickly enter the chemical drug market [3][4]. - The company employs an open collaboration strategy for innovative drug development, working with top scientists, research institutions, and investing in biotech companies with potential [4][5]. Group 2: Investment Standards - HaiTe Biopharma has established three key standards for external investments: alignment with industry technology trends, strategic synergy with existing drug areas, and feasibility and commercialization potential of the technology [5][6]. - The company focuses on investing in cell and gene therapy (CGT) technologies, which are seen as the next significant direction in drug development [5][6]. - The investment strategy emphasizes the importance of addressing unmet clinical needs, particularly in oncology and neurological diseases, where there is substantial patient demand and limited existing therapies [7]. Group 3: Market Positioning - The company aims to solidify its current position in the generic drug market while pursuing innovative drugs and frontier investments for future growth [7]. - HaiTe Biopharma's approach reflects a strategic positioning to transition from high-speed growth to high-quality development, focusing on true innovation rather than mere imitation [7].